DUBLIN--(BUSINESS WIRE)--The "Global Antidepressants Market - Segmented by Antidepressant Therapies, Depressive Disorders, and Geography 2017 - 2022" report has been added to Research and Markets' offering.
The global antidepressants market is estimated to grow to approximately USD 13.4 billion by 2020, at a CAGR of 1.8%
Depression affects an estimated 121 million people worldwide and the antidepressant drug market reached sales of almost USD 11 billion in 2014. This study provides the market analysis for the major drug classes used for the treatment of depression.
An increasing number of people suffering from stress and increase in the awareness level of disease state and clinical needs are factors that drive the market.
Poor efficacy and safety profiles, repeated drug failures in clinical trials, availability of generics and weak pipelines are the restraints faced by the market.
The market for antidepressants has been segmented based on the various classes of drugs that are generally used for the treatment of these psychiatric conditions. Various drug classes considered while estimating the overall market are selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tetracyclic antidepressants (TeCAs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), benzodiazepines, beta-blockers, atypical antipsychotics, and anticonvulsants. These drug classes cover major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD) and panic disorder (PD).
Key Topics Covered:
1. Introduction
2. Executive summary
3. Market overview
4. Porter's five force analysis
5. Market segmentation
6. Competitive landscape
7. Company profiles
- H. Lundbeck
- AstraZeneca
- Eli Lilly and Company
- Forest Laboratories
- Pfizer Inc.
- GlaxoSmithKline
- Bristol-Myers Squibb Company
For more information about this report visit https://www.researchandmarkets.com/research/l9w7v6/global
